Paxlovid copycat pills put to the test – but study pulled
NCT ID NCT06397144
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Pfizer study aimed to check if new combination tablets of nirmatrelvir/ritonavir (the drug in Paxlovid) work the same as the current marketed version. About 28 healthy adults were to receive single doses of different tablet forms under fasting conditions. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nirmatrelvir/ritonavir (Paxlovid)
- What this could lead to
- If successful, this could show that new tablet formulations work the same as the current Paxlovid, potentially offering more manufacturing options.
- What could go wrong
- This trial was withdrawn before enrolling anyone, so no data will be collected. It was a small, early-phase study in healthy people, not patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOLOGICAL AVAILABILITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates